Allakos Inc. operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.
Allakos Inc. NASDAQ:ALLK
Today's live share price, quote history, chart & news
About Allakos Inc.
|Exchange||NASDAQ Stock Exchange|
|Full time employees||90|